Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.

@article{Tutuncu2005FcgammaRT,
  title={Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.},
  author={Zuhre N Tutuncu and Arthur J Kavanaugh and Nathan J. Zvaifler and Maripat Corr and Reena Deutsch and David Joseph Boyle},
  journal={Arthritis and rheumatism},
  year={2005},
  volume={52 9},
  pages={2693-6}
}
OBJECTIVE To determine whether polymorphisms in Fcgamma receptor type IIIA (FcgammaRIIIA) correlate with clinical efficacy in patients with rheumatoid arthritis (RA) and patients with psoriatic arthritis (PsA) being treated with tumor necrosis factor alpha (TNFalpha) inhibitors. METHODS The study group comprised 30 patients with RA and 5 patients with PsA… CONTINUE READING